ADRENOMEDULLINE FOR ASSESSING CONGESTION IN INDIVIDUAL WITH ACUTE HEART FAILURE Russian patent published in 2025 - IPC G01N33/68 G01N33/74 

Abstract RU 2835424 C2

FIELD: medicine.

SUBSTANCE: group of inventions relates to diagnostics of stagnation of intra- and extracellular fluid in conditions of heart failure. Method for diagnosing stagnation of intra- and extracellular fluid in an individual with heart failure involves determining the level of proadrenomedullin or fragments thereof from at least 5 amino acids in a sample selected from whole blood, serum or plasma; correlation of said level of proadrenomedullin or its fragments with a degree of stagnation or diagnosis of stagnation, wherein an increased level above a threshold value is an indicator of stagnation or degree of stagnation, where said proadrenomedullin or a fragment thereof is selected from a group comprising MR-pro-ADM with SEQ ID NO: 3, mature ADM-NH2 with SEQ ID NO: 4, where threshold value is for mature ADM-NH2 with SEQ ID NO: 4 from 50 to 100 pg/ml, for MR-pro-ADM with SEQ ID No: 3 from 0.5 to 1.5 nmol/l. Also disclosed is a method for assessing stagnation or residual stagnation after a therapy or intervention in stagnation in an individual, using proadrenomedulline or fragments thereof for diagnosing stagnation or assessing or monitoring the degree of stagnation, to assess the elimination of stagnation or residual stagnation after therapy or intervention in case of stagnation.

EFFECT: group of inventions provides an early surrogate stagnation marker.

16 cl, 5 dwg, 22 tbl, 12 ex

Similar patents RU2835424C2

Title Year Author Number
ANTIBODY AGAINST ADRENOMEDULLIN (ADM), OR FRAGMENT OF ANTI-ADM ANTIBODY, OR ANTI-ADM NON-IG FRAME FOR USE IN INTERVENTION AND THERAPY OF HYPEREMIA IN PATIENT 2017
  • Voors, Adriaan
RU2762059C2
THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) 2018
  • Struck, Joachim
  • Bergmann, Andreas
RU2776811C2
THERAPEUTIC GUIDANCE AND/OR MONITORING THERAPY FOR TREATING SHOCK 2020
  • Bergmann, Andreas
RU2835616C1
ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE 2014
  • Bergmann Andreas
RU2673455C2
ADRENOMEDULLIN (ADM) FOR DIAGNOSTICS AND/OR PREDICTION OF DEMENTIA AND ANTIADRENOMEDULLIN-BINDING AGENT FOR USE IN THERAPY OR PREVENTION OF DEMENTIA 2019
  • Melander, Olle
RU2811309C2
HISTONES AND/OR proADM AS MARKERS INDICATING ADVERSE EVENT 2017
  • Tsira Tim
  • Shenikhen Andre
  • Enkam Ann
  • Krop Manne
  • Kurdt Ingo
  • Sharl Per-Emmanyuel
RU2765212C2
HISTONES AND/OR proADM AS MARKERS TESTIFYING ABOUT ORGAN DYSFUNCTION 2017
  • Tsira Tim
  • Drejer Frauke
  • Enkam Ann
  • Krop Manne
  • Sharl Per-Emmanyuel
RU2764766C2
BIOMARKERS FOR DIAGNOSIS, PREDICTION, ASSESSMENT AND STRATIFICATION OF FAINTING THERAPY 2013
  • Shtruk Joakhim
  • Melander Olle
  • Fedorovski Artur
RU2613885C2
METHOD FOR PREDICTION OF CHRONIC KIDNEY DISEASE RISK 2016
  • Bergmann Andreas
  • Melander Olle
RU2733471C2
PREDICTION OF CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 2013
  • Girsdorf Sven
  • Tamm Mikhael
  • Shtolts Dajana
RU2688168C2

RU 2 835 424 C2

Authors

Bergmann, Andreas

Voors, Adriaan

Dates

2025-02-25Published

2022-08-30Filed